These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 27282763)

  • 21. Percutaneous Closure of Patent Foramen Ovale in Patients With Migraine: The PREMIUM Trial.
    Tobis JM; Charles A; Silberstein SD; Sorensen S; Maini B; Horwitz PA; Gurley JC
    J Am Coll Cardiol; 2017 Dec; 70(22):2766-2774. PubMed ID: 29191325
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The IrisFIT Patent Foramen Ovale Closure Device in Patients With History of Cryptogenic Embolization.
    Hornung M; Bertog SC; Gafoor S; Reinartz M; Vaskelyte L; Hofmann I; Sievert K; Matic P; Grunwald I; Sievert H
    J Invasive Cardiol; 2019 Nov; 31(11):319-324. PubMed ID: 31522140
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Residual Shunt after Patent Foramen Ovale Device Closure in Patients With Cryptogenic Stroke: Serial Bubble Contrast Transesophageal Echocardiography Data.
    Moon J; Kim M; Oh PC; Shin DH; Park HM; Jo YY; Lee JS; Kang WC
    J Stroke Cerebrovasc Dis; 2019 Feb; 28(2):347-353. PubMed ID: 30396838
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Figulla PFO occluder versus Amplatzer PFO occluder for percutaneous closure of patent foramen ovale.
    Saguner AM; Wahl A; Praz F; de Marchi SF; Mattle HP; Cook S; Windecker S; Meier B
    Catheter Cardiovasc Interv; 2011 Apr; 77(5):709-14. PubMed ID: 20931665
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transcatheter interatrial septal defect closure in a large cohort: midterm follow-up results.
    Aytemir K; Oto A; Özkutlu S; Canpolat U; Kaya EB; Yorgun H; Şahiner L; Sunman H; Ateş AH; Kabakçı G
    Congenit Heart Dis; 2013; 8(5):418-27. PubMed ID: 23601507
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Post-Market Clinical Follow-Up With the Patent Foramen Ovale Closure Device IrisFIT (Lifetech) in Patients With Stroke, Transient Ischemic Attack, or Other Thromboembolic Events.
    Sievert K; Yu J; Bertog S; Hornung M; von Bardeleben RS; Gafoor S; Reinartz M; Matic P; Hofmann I; Grunwald I; Schnelle N; Sievert H
    Cardiovasc Revasc Med; 2021 Sep; 30():72-75. PubMed ID: 33097460
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Echocardiographic findings in simple and complex patent foramen ovale before and after transcatheter closure.
    Vitarelli A; Mangieri E; Capotosto L; Tanzilli G; D'Angeli I; Toni D; Azzano A; Ricci S; Placanica A; Rinaldi E; Mukred K; Placanica G; Ashurov R
    Eur Heart J Cardiovasc Imaging; 2014 Dec; 15(12):1377-85. PubMed ID: 25139906
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term follow-up after PFO device closure: Outcomes and Complications in a Single-center Experience.
    Taggart NW; Reeder GS; Lennon RJ; Slusser JP; Freund MA; Cabalka AK; Cetta F; Hagler DJ
    Catheter Cardiovasc Interv; 2017 Jan; 89(1):124-133. PubMed ID: 27027873
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multidisciplinary Assessment in Optimising Results of Percutaneous Patent Foramen Ovale Closure.
    Davies A; Ekmejian A; Collins N; Bhagwandeen R
    Heart Lung Circ; 2017 Mar; 26(3):246-250. PubMed ID: 27555053
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of residual shunt rates in five devices used to treat patent foramen ovale.
    Matsumura K; Gevorgyan R; Mangels D; Masoomi R; Mojadidi MK; Tobis J
    Catheter Cardiovasc Interv; 2014 Sep; 84(3):455-63. PubMed ID: 24550064
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Persistence of residual shunt at 6 and 12 months after transoesophageal echocardiography-guided percutaneous closure of a patent foramen ovale for cryptogenic stroke.
    Witte LS; El Bouziani A; Beijk MAM; Robbers-Visser D; Coutinho JM; Tijssen JGP; Straver B; Bouma BJ; de Winter RJ
    Heart; 2024 Sep; 110(19):1172-1179. PubMed ID: 39122559
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of Discontinuation of Antithrombotic Therapy Following Closure of Patent Foramen Ovale in Patients With Cryptogenic Embolism.
    Wintzer-Wehekind J; Alperi A; Houde C; Côté JM; Guimaraes LFC; Côté M; Rodés-Cabau J
    Am J Cardiol; 2019 May; 123(9):1538-1545. PubMed ID: 30792001
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Medium-term results of transcatheter closure of patent foramen ovale (PFO) with Amplatzer PFO and Cribriform occluders.
    Białkowski J; Wawrzyńczyk M; Karwot B; Fiszer R; Knop M; Szkutnik M
    Kardiol Pol; 2012; 70(11):1142-6. PubMed ID: 23180522
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recurrent stroke in patients with patent foramen ovale: An observational prospective study of percutaneous closure of PFO versus non-closure.
    Mirzada N; Ladenvall P; Hansson PO; Eriksson P; Dellborg M
    Int J Cardiol; 2015 Sep; 195():293-9. PubMed ID: 26056962
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multidisciplinary assessment of PFO with substantial right-to-left shunting and medium-term follow-up after PFO device closure: A single-center experience.
    He L; Cheng GS; Du YJ; Zhang YS
    J Interv Cardiol; 2017 Aug; 30(4):362-367. PubMed ID: 28568903
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and efficacy of Cardi-O-fix occluder for percutaneous closure of a patent foramen ovale: A single-center prospective study.
    Zhao E; Liu W; Zhang Y; Cheng G; Du Y; He L; Wang X; He X
    Medicine (Baltimore); 2017 Apr; 96(14):e6572. PubMed ID: 28383438
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patent foramen ovale transcatheter closure vs. medical therapy on recurrent vascular events: a systematic review and meta-analysis of randomized controlled trials.
    Rengifo-Moreno P; Palacios IF; Junpaparp P; Witzke CF; Morris DL; Romero-Corral A
    Eur Heart J; 2013 Nov; 34(43):3342-52. PubMed ID: 23847132
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term propensity score-matched comparison of percutaneous closure of patent foramen ovale with medical treatment after paradoxical embolism.
    Wahl A; Jüni P; Mono ML; Kalesan B; Praz F; Geister L; Räber L; Nedeltchev K; Mattle HP; Windecker S; Meier B
    Circulation; 2012 Feb; 125(6):803-12. PubMed ID: 22238228
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term follow-up outcomes in a real-world study cohort after percutaneous patent foramen ovale closure.
    Ateş AH; Yorgun H; Canpolat U; Şener YZ; Okşul M; Kaya EB; Şahiner ML; Topcuoğlu MA; Arsava EM; Aytemir K
    Turk Kardiyol Dern Ars; 2021 Jan; 49(1):29-39. PubMed ID: 33390571
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical evaluation of a novel occluder device (Occlutech) for percutaneous transcatheter closure of patent foramen ovale (PFO).
    Krizanic F; Sievert H; Pfeiffer D; Konorza T; Ferrari M; Figulla HR
    Clin Res Cardiol; 2008 Dec; 97(12):872-7. PubMed ID: 18696022
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.